相关实验视频

Updated: Feb 28, 2026

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

使用多面模型破译RAC1-SPTAN1在ARPKD细胞生成中的影响

Shohei Kuraoka¹, Yuhei Higashi¹, Suguru Saito²

¹Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|February 26, 2026

概括

降低的SPTAN1水平通过增加RAC1/c-FOS信号来驱动自体逆性多囊性病 (ARPKD) 囊的形成. 在模型中恢复SPTAN1可以缓解疾病表型,这表明表观基因组编辑是ARPKD的治疗策略.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

自体逆性多囊性病 (ARPKD) 导致严重的囊和功能障碍,缺乏有效的治疗方法.
目前的小鼠模型无法完全复制人类ARPKD囊性表型.
新型模型对于理解ARPKD病原体和识别治疗点至关重要.

研究的目的:

研究ARPKD囊形成背后的分子机制.
确定ARPKD的新型治疗点.
开发和利用ARPKD研究的先进模型.

主要方法:

开发脏器官在芯片上的模型,模仿患者的远端脏囊.
使用转基因小鼠和患者脏样本进行验证.
采用了转录组学,实时成像,单细胞RNA-seq和CRISPR激活.

主要成果:

减少的SPTAN1水平被确定为RAC1激活和ARPKD病理学的关键调节者.
缺少SPTAN1导致远端脏囊,RAC1/c-FOS升高,以及信号的改变.
在模型中,CRISPR介导的SPTAN1恢复改善了囊性表型和正常化的分子通路.

结论:

SPTAN1是ARPKD发病的一个关键因素,调节囊的发育.
改变的信号传递和RAC1/c-FOS激活是ARPKD的核心.
针对SPTAN1的表观基因组编辑显示了ARPKD的治疗潜力.

关键词:

在RAC1中,RAC1是指RAC1.在SPTAN1中,我们可以使用SPTAN1.脏脏脏是什么?尼弗朗 (nephron) 是一个名字.这是一种有机物质的有机物质.器官在芯片上的器官多囊性脏疾病多囊性脏疾病

更多相关视频

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys

Published on: December 2, 2014

相关概念视频

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...